Rain Oncology Inc (RAIN) 2022年年度报告「NASDAQ」.pdf

1、Table of ContentsiUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2022ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EX

2、CHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40356Rain Oncology Inc.(Exact name of Registrant as specified in its Charter)Delaware82-1130967(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)8000 Jarvis Avenue,Suite 204Ne

3、wark,CA94560(Address of principal executive offices)(Zip Code)Registrants telephone number,including area code:(510)953-5559Former name,former address and former fiscal year,if changed since last report:Rain Therapeutics Inc.Securities registered pursuant to Section 12(b)of the Act:Title of each cla

4、ssTrading Symbol(s)Name of each exchange on which registeredCommon Stock,par value$0.001 per shareRAINThe Nasdaq Global Select MarketSecurities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the Registrant is a well-known seasoned issuer,as defined in Rule 405 of the Se

5、curities Act.Yes No Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d)of the Act.Yes No Indicate by check mark whether the Registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 durin

6、g the preceding 12 months(or for suchshorter period that the Registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to